drugset / Trial / NCT00295607

Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients

NCT00295607

Phase 2 Completed 138 enrolled Astellas Pharma Inc
RandomizedParallel-groupOpen-labelPrevention

Summary

This is an exploratory study to evaluate the impact of eliminating steroid administration upon viral HCV load at 12 months measured by quantitative serum HCV-RNA determination in patients transplanted for HCV cirrhosis.

Timeline

Start
2005-06
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Daclizumab Monoclonal antibody
Background Tacrolimus Small molecule